Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript

Jazz Pharmaceuticals stock falls after Phase 3 trial results By Investing.com

Jazz Pharmaceuticals stock falls after Phase 3 trial results

Jazz Pharmaceuticals And Zymeworks Ziihera Success: A Pleasant Surprise

Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals names Renee Gala as next CEO By Investing.com

Jazz Pharmaceuticals names Renee Gala as next CEO

Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of -62.75% and 8.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?

Jazz (JAZZ) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B

Jazz Pharmaceuticals and Boston Beer Company have been highlighted as Zacks Bull and Bear of the Day

Jazz Pharmaceuticals and Boston Beer Company are part of the Zacks Bull and Bear of the Day article.

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors-

Zacks.com featured highlights include EverQuote, Jazz Pharmaceuticals, The Progressive, Sony and NatWest

EverQuote, Jazz Pharmaceuticals, The Progressive, Sony and NatWest have been highlighted in this Screen of The Week article.

Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Jazz Pharmaceuticals: 60 % Kurspotenzial durch Rekordumsatz und gewonnenes Patentduell

Die Aktie von Jazz bleibt weiterhin hochinteressant. Im November 2024 berichtete ich sowohl an dieser Stelle als auch anschließend in unserem Growth-Magazin über die Potenziale des Unternehmens. Hierbei...

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Jazz Pharmaceuticals plc 2024 Q4 - Results - Earnings Call Presentation

Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of 13.99% and 2.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, announced results from a Phase 1b/2 clinical trial demonstrating the company’s investigational CD47-blocker evorpacept in combination with Jazz Pharmaceuticals’ zanidatamab generates promising anti-tumor activity in patients w...

Jazz Pharmaceuticals: Kurspotenzial von 50 % durch neue Therapie von aggressivem Lungenkrebs

Die Innovationskraft von Unternehmen im Megatrend Biopharmazeutika bringt seit Monaten attraktive Anlageoptionen hervor. Mit dem Potenzial, komplexe Krankheiten wie Krebs und genetische Erkrankungen effektiv...

Jazz Pharmaceuticals plc (JAZZ) Q3 2024 Earnings Call Transcript

Global Oral Transmucosal Drugs Market Size To Exceed USD 62.3 Billion By 2033 | CAGR Of 6.5%

The Global Oral Transmucosal Drugs Market Size was Valued at USD 33.2 Billion in 2023 and the Worldwide Oral Transmucosal Drugs Market Size is Expected to Reach USD 62.3 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: ZIM Laboratories Limited, Sunovion Pharmaceuticals, Inc, C.L.Pharm Co., Ltd, IntelGenx Corp, CURE Pharmaceutical, Seoul Pharmaceuticals, Aquestive Therapeutics, Inc, Jazz Pharmaceuticals, plc, NAL Pharma, Novartis AG,...

Jazz Pharmaceuticals plc 2024 Q1 - Results - Earnings Call Presentation

Biotech-Einhorn! FDA Zulassung für das CBD-Wunder?!

Anzeige / WerbungEin einziges Medikament, das auf CBD basiert ist bislang von der FDA zur Verwendung zugelassen worden. Resultat: Der irische Pharmakonzern Jazz Pharmaceuticals hat für 7,2 Milliard...

Earnings call: Jazz Pharmaceuticals reports robust 2023 financials By Investing.com

Earnings call: Jazz Pharmaceuticals reports robust 2023 financials

Jazz Pharmaceuticals PLC (JAZZ) Q4 2023 Earnings Call Transcript

Jazz Pharmaceuticals plc 2023 Q4 - Results - Earnings Call Presentation